Jpmorgan Chase & CO Zynerba Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.33 - $1.39 $3,762 - $15,850	11,403 Added 120.39%	20,875 $26,000
Q2 2023 Aug 11, 2023	BUY	$0.3 - $0.43 $1,719 - $2,465	5,733 Added 153.33%	9,472 $3,000
Q1 2023 May 11, 2023	BUY	$0.4 - $0.67 $1,290 - $2,162	3,227 Added 630.27%	3,739 $1,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $0.72 $225 - $324	451 Added 739.34%	512 $0
Q3 2021 Nov 12, 2021	BUY	$3.72 - $5.35 $226 - $326	61 New	61 $0

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.